Tudriqev (vusolimogene oderparepvec-wtpg) NDC 83616-106

NDC codes

FDA NDC Directory

Product NDC (as listed)83616-106Labeler and product segments. Claims need a package NDC.

Product NDC at billing width83616-0106Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
83616-106-11	83616010611	1 VIAL, SINGLE-DOSE in 1 CARTON (83616-106-11) / 1 mL in 1 VIAL, SINGLE-DOSE (83616-106-01)Marketed from Sep 4, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tudriqev
Generic name (nonproprietary): vusolimogene oderparepvec-wtpg
Active ingredients: Vusolimogene oderparepvec — 1000000 [PFU]/mL
Dosage form: Injection, Suspension
Route: Intratumor
Labeler: Replimune, Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125827
Marketing start: Sep 4, 2026
Listing expires: Dec 31, 2027
Identifiers: Product ID 83616-106_1ddc4551-7fe8-4d58-952c-1d0dd1f6af67SPL ID 1ddc4551-7fe8-4d58-952c-1d0dd1f6af67

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N483616010611 followed by a unit qualifier and the quantity

Package 83616-0106-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

Other NDCs under BLA 125827

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 125827
Product	Strength	Form · route	Labeler	Product NDC
Tudriqevvusolimogene oderparepvec-wtpg	Vusolimogene oderparepvec 10000000 [PFU]/mL	Injection, SuspensionIntratumor	Replimune, Inc.	83616-107